Anthrax
Firm negotiates vaccine rights
Published in TB and Outbreaks Week, September 23rd, 2003
No deal has been made, and the company's vaccine is still years away from gaining regulatory approval. Still, the company's stock closed up nearly 23% on the announcement.
Brisbane-based VaxGen issued a news release that said it was negotiating with the Health Protection Agency for England and Wales.
VaxGen is developing the vaccine, dubbed rPA102, under a $16.2 million contract from the National Institute of Allergy and Infectious Diseases, one of the U.S. National...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Infectious Disease Therapy
Novel carbapenems show promise for treatment of drug-resistant pathogens - Infectious Disease Therapy
Novel parenteral cephalosporin shows promise against MRSA and other pathogens - Infectious Disease Therapy
Garenoxacin highly active against resistant Streptococcus pneumoniae - Infectious Disease Therapy
Telithromycin highly active against resistant respiratory tract pathogens - Malaria Therapy
Ankyrin peptide blocks falcipain-2-mediated malaria parasite release - Malaria Therapy
Artesunate-primaquine antimalarial regimen highly effective in Thailand - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
